alpha-aminopyridine has been researched along with MPTP Neurotoxicity Syndrome in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (50.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ci, L; Dong, H; Fei, J; Huang, F; Li, Q; Liu, Z; Ma, Y; Shen, C; Shen, R; Sun, R; Wang, J; Wang, Z; Yu, M; Zhang, X | 1 |
| Li, M; Liu, Q; Ma, C; Qiu, S; Ren, H; Shi, FD; Wood, K; Yang, X | 1 |
| Iwashita, A; Matsuoka, N; Mihara, T | 1 |
| Akahane, A; Aoki, S; Iwashita, A; Matsuda, R; Matsuoka, N; Mihara, K; Mihara, T; Mitani, Y; Yamamoto, H; Yarimizu, J | 1 |
4 other study(ies) available for alpha-aminopyridine and MPTP Neurotoxicity Syndrome
| Article | Year |
|---|---|
Partial depletion and repopulation of microglia have different effects in the acute MPTP mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Aminopyridines; Animals; Behavior, Animal; Cyclooxygenase 2; Cytokines; Disease Models, Animal; Dopaminergic Neurons; Inflammation Mediators; Male; Membrane Glycoproteins; Mice; Mice, Inbred C57BL; Microglia; MPTP Poisoning; Neuroprotective Agents; Pyrroles; Receptors, Immunologic | 2021 |
Depletion of microglia augments the dopaminergic neurotoxicity of MPTP.
Topics: Aminopyridines; Animals; Dopaminergic Neurons; Inflammation Mediators; Leukocytes; Male; Mice; Mice, Knockout; Microglia; MPTP Poisoning; Pyrroles; Receptors, Granulocyte-Macrophage Colony-Stimulating Factor | 2018 |
A novel adenosine A(1) and A(2A) receptor antagonist ASP5854 ameliorates motor impairment in MPTP-treated marmosets: comparison with existing anti-Parkinson's disease drugs.
Topics: Aminopyridines; Analysis of Variance; Animals; Antiparkinson Agents; Callithrix; Disease Models, Animal; Dose-Response Relationship, Drug; Female; Male; Motor Activity; Movement Disorders; MPTP Poisoning; Piperazines; Purinergic Antagonists; Time Factors | 2008 |
Pharmacological characterization of a novel, potent adenosine A1 and A2A receptor dual antagonist, 5-[5-amino-3-(4-fluorophenyl)pyrazin-2-yl]-1-isopropylpyridine-2(1H)-one (ASP5854), in models of Parkinson's disease and cognition.
Topics: Adenosine; Adenosine A1 Receptor Antagonists; Adenosine A2 Receptor Antagonists; Aminopyridines; Animals; CHO Cells; Cognition Disorders; Cricetinae; Cricetulus; Dopamine; Haloperidol; Humans; Male; Memory Disorders; Mice; Mice, Inbred C57BL; MPTP Poisoning; Phenethylamines; Piperazines; Rats; Rats, Inbred F344; Rats, Wistar; Receptor, Adenosine A1; Receptor, Adenosine A2A; Scopolamine | 2007 |